Adial Pharmaceuticals, Inc (ADIL) Dividend History

Company News

• Evolving Landscape of Mental Health Segment: Key Market Insights of the Latest Published Substance Use Disorders Report — Alcohol Use Disorder, Cocaine Use Disorder, Opioid Use Disorder, and Cannabis Use Disorder | DelveInsight

  The substance use disorder market is expected to grow between 2025 and 2034, driven by greater awareness, the introduction of new therapies, and ongoing research and development efforts. The report covers the market assessment of Alcohol Use Disorder, Cocaine Use Disorder, Opioid Use Disorder, and Cannabis Use Disorder.

  GlobeNewswire Inc.

  Featured Companies: BTAI CMND INDV
• Adial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04

  Adial Pharmaceuticals received positive feedback from the FDA on its proposed in vitro bridging strategy for its drug candidate AD04, a key step towards advancing the drug into Phase 3 clinical trials for the treatment of alcohol use disorder.

  GlobeNewswire Inc.
• Adial Pharmaceuticals Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

  Adial Pharmaceuticals announced positive results from a pharmacokinetics study of its investigational drug AD04 for the treatment of Alcohol Use Disorder. The study results support the planned near micro-dosing regimen and the company's plans to pursue FDA approval under the 505(b)(2) regulatory pathway.

  GlobeNewswire Inc.
• Alcohol Use Disorder Market Set for Remarkable Growth During the Study Period (2020–2034) | DelveInsight

  The alcohol use disorder market is expected to show positive growth, with growing awareness about AUD and reduced stigma surrounding mental health issues encouraging more individuals to seek treatment during the forecast period (2024–2034).

  GlobeNewswire Inc.

  Featured Companies: CMND CORT
• EXCLUSIVE: Adial Pharmaceuticals Moves Forward To Second Cohort In Pharmacokinetics Study of AD04 For Alcohol Use Disorder - Benzinga

  Adial Pharmaceuticals has progressed to the second cohort in the pharmacokinetics study of its lead investigational drug AD04 for Alcohol Use Disorder. The study is expected to be completed in the fourth quarter of 2024, and the results will provide insights for the upcoming Phase 3 clinical trial.

  Benzinga